Study of Tabrecta for NSCLC with exon 14 skipping
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study follows people in South Korea who have a specific lung cancer genetic change called “exon 14 skipping” and are going to take Tabrecta (capmatinib). It helps collect real-world safety and results for using this medicine under routine care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign an informed consent form before joining.
- You have non-small cell lung cancer (NSCLC) with the “exon 14 skipping” mutation, proven from a tissue sample or blood test.
- Your doctor plans for you to start taking Tabrecta (capmatinib) based on the approved (locally labeled) use.
- You must have no known medical reasons you cannot take Tabrecta according to the label.
- Your medical records must be accessible to the study team.
- You must be willing to participate and provide consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at real-world safety data for patients in South Korea who are taking Capivasertib as prescribed by their doctor according to the approved label. It helps ensure the drug continues to be safe and effective for people who need it.
This study tests an oral drug called capmatinib for people whose cancers have specific changes in the MET gene (except for one type of lung cancer). It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a targeted treatment given before and after surgery for people with a specific type of early-stage lung cancer that has a BRAF V600 or MET exon 14 mutation. The goal is to see if the treatment helps shrink the tumor before surgery and prevent it from coming back afterward.
This study looks at how well the drug taletrectinib works for people with a specific type of advanced lung cancer (ROS1-positive NSCLC) whose cancer has gotten worse after treatment with the drug entrectinib. It aims to help doctors understand real-world outcomes for these patients.
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
This trial tests a new drug, SCTB14, as a first treatment for advanced non-small cell lung cancer that has a high level of PD-L1. It aims to see if the drug is safe and effective for people who haven't had other treatments for their cancer.
Hear when a new Non-Small-Cell Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.